Articles tagged with: BHQ880

News»

[ by and | May 24, 2013 4:23 pm | 8 Comments ]
The Future Of Treatment For Multiple Myeloma

In a recent review article pub­lished in the journal Clinical Cancer Re­search, two myeloma experts from the Dana-Farber Cancer In­sti­tute, Dr. Nikhil Munshi and Dr. Kenneth Anderson, review the latest strategies in the treat­ment of mul­ti­ple myeloma.

In their article, the experts discuss newer ther­a­pies that appear to be promising in clin­i­cal and pre­clin­i­cal stud­ies.

According to the physicians, com­bi­na­tion ther­a­pies that spe­cif­i­cally target a patient’s ge­netic form of the dis­ease will be re­quired for long-term dis­ease con­trol and ultimately a cure.

Some Historical Perspective

In their review article, Drs. Munshi and …

Read the full story »

News»

[ by | Updated: Dec 16, 2012 7:00 pm | 10 Comments ]
ASH 2012 Multiple Myeloma Update – Day Three: Early Morning Oral Session

Today is the third day of the American Society of Hematology (ASH) 2012 annual meeting in Atlanta, and it is packed full with multiple myeloma-related presentations. Presentations started early in the morning and will con­tinue through the afternoon.

Over the course of today, at least 11 different oral sessions, many of which are being held simultaneously, will include presentations about myeloma-related topics.  The Beacon will summarize presentations from the four most relevant sessions in updates such as this one.  This update, in particular, covers presentations from the first of those four oral …

Read the full story »

News»

[ by | Nov 19, 2012 1:03 pm | 5 Comments ]
New Multiple Myeloma Treatments On The Horizon (ASH 2012)

During the upcoming annual meeting of the American Society of Hematology (ASH), which will be held December 8 through 11 in Atlanta, results will be presented from clin­i­cal trials involving a number of poten­tial new drugs under devel­op­ment for the treat­ment of multiple myeloma.

In particular, results for newer, lesser known agents that are in the early stages of clin­i­cal devel­op­ment will take center stage. These agents in­clude ARRY-520 (filanesib), BHQ880, circularly permuted TRAIL, daratumumab, dinaciclib, lorvotuzumab mertansine, oprozomib, and tabalumab.

According to the recently …

Read the full story »

News»

[ by and | Oct 19, 2011 12:55 pm | 11 Comments ]
Experts Review Current And Future Research Into New Multiple Myeloma Treatments

Earlier this year, an inter­na­tional group of myeloma experts pub­lished a review of ongoing re­search into new myeloma treat­ments.  This review not only described a wide range of po­ten­tial new myeloma treat­ments, but also in­cluded the experts' thoughts on where re­search into new treat­ments should go in the future.

Given the recent new drug appli­ca­tion for car­filz­o­mib and the upcoming annual meeting of the American Society of He­ma­tol­ogy -- which undoubtedly will host dis­cus­sions of many po­ten­tial new myeloma treat­ments -- it seems an appro­pri­ate time to go back to the experts' review from …

Read the full story »

News, Opinion»

[ by | Sep 23, 2011 3:46 pm | 4 Comments ]
Recent Advances In The Treatment Of Myeloma Bone Disease

Multiple myeloma is the most frequent cancer to involve the skeleton, with up to 80 percent of patients having bone disease. Although fewer patients appear to have bone involvement more recently, it is still a major source of both complications and death among patients with myeloma.

Bone disease is so severe in myeloma because the normal bone remodeling process is disrupted. In normal individuals, damaged bone is removed by bone-destroying cells, the osteoclasts, and then bone is replaced by bone-forming cells, the osteoblasts. In myeloma, the number and activity of the bone-destroying …

Read the full story »

News»

[ by | Jul 24, 2009 8:48 am | One Comment ]
Anti-DKK1 Antibody As New Treatment For Myeloma Bone Disease

A new study appearing in the July 9 issue of Blood discussed a potential therapeutic treatment that focuses on osteoblasts, the cells responsible for bone formation.

Myeloma patients commonly have high serum DKK1 levels, which may decrease with response to therapy for myeloma. DKK1, an important regulator of bone formation, has previously been associated with bone disease in cancers of the esophagus, lungs, prostate, and colon. However, DKK1 has recently emerged as a therapeutic target for suppressed bone formation. The study analyzed the effect of an antibody that neutralizes DKK1, called

Read the full story »